Cargando…

Single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study

BACKGROUND: Several RCT studies including ours, seem to prove the role of Botulinum toxin type A (BTX-A) in the treatment of trigeminal neuralgia (TN), but no standardized dosing regimen has been established. In our study, we compare two different methods of administration: single-dose or repeated-d...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Haifeng, Lian, Yajun, Xie, Nanchang, Chen, Chen, Zheng, Yake
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552618/
https://www.ncbi.nlm.nih.gov/pubmed/28799056
http://dx.doi.org/10.1186/s10194-017-0793-3
_version_ 1783256477819994112
author Zhang, Haifeng
Lian, Yajun
Xie, Nanchang
Chen, Chen
Zheng, Yake
author_facet Zhang, Haifeng
Lian, Yajun
Xie, Nanchang
Chen, Chen
Zheng, Yake
author_sort Zhang, Haifeng
collection PubMed
description BACKGROUND: Several RCT studies including ours, seem to prove the role of Botulinum toxin type A (BTX-A) in the treatment of trigeminal neuralgia (TN), but no standardized dosing regimen has been established. In our study, we compare two different methods of administration: single-dose or repeated-dose strategy which was most frequently applied over the years in our centre. METHODS: An open-label trail was conducted. One hundred patients with classic TN symptoms were recruited, and randomly and equally apportioned to single- or repeated-dose group. Patients in the single-dose group received a local BTX-A injection of 70 to 100 U. The repeated-dose group received an initial BTX-A injection of 50 to 70 U and then another of equal volume 2 weeks later. All patients were followed for 6 months. RESULTS: In the single- and repeated-dose groups, 44 and 37, respectively, completed the entire study. The groups were statistically similar in TN frequency, time between treatment and effect, time to peak effect, VAS scores, and rates of adverse reactions (latency and duration). However, the single-dose group experienced significantly longer duration of effect (P = 0.032). CONCLUSIONS: The single- and repeated-dosing BTX-A regimens were largely comparable in efficacy and safety. This study suggests that repeated dosing has no advantage over single dosing of BTX-A for TN. Dosing should be adjusted for the individual patient.
format Online
Article
Text
id pubmed-5552618
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-55526182017-08-25 Single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study Zhang, Haifeng Lian, Yajun Xie, Nanchang Chen, Chen Zheng, Yake J Headache Pain Research Article BACKGROUND: Several RCT studies including ours, seem to prove the role of Botulinum toxin type A (BTX-A) in the treatment of trigeminal neuralgia (TN), but no standardized dosing regimen has been established. In our study, we compare two different methods of administration: single-dose or repeated-dose strategy which was most frequently applied over the years in our centre. METHODS: An open-label trail was conducted. One hundred patients with classic TN symptoms were recruited, and randomly and equally apportioned to single- or repeated-dose group. Patients in the single-dose group received a local BTX-A injection of 70 to 100 U. The repeated-dose group received an initial BTX-A injection of 50 to 70 U and then another of equal volume 2 weeks later. All patients were followed for 6 months. RESULTS: In the single- and repeated-dose groups, 44 and 37, respectively, completed the entire study. The groups were statistically similar in TN frequency, time between treatment and effect, time to peak effect, VAS scores, and rates of adverse reactions (latency and duration). However, the single-dose group experienced significantly longer duration of effect (P = 0.032). CONCLUSIONS: The single- and repeated-dosing BTX-A regimens were largely comparable in efficacy and safety. This study suggests that repeated dosing has no advantage over single dosing of BTX-A for TN. Dosing should be adjusted for the individual patient. Springer Milan 2017-08-10 /pmc/articles/PMC5552618/ /pubmed/28799056 http://dx.doi.org/10.1186/s10194-017-0793-3 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research Article
Zhang, Haifeng
Lian, Yajun
Xie, Nanchang
Chen, Chen
Zheng, Yake
Single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study
title Single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study
title_full Single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study
title_fullStr Single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study
title_full_unstemmed Single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study
title_short Single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study
title_sort single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552618/
https://www.ncbi.nlm.nih.gov/pubmed/28799056
http://dx.doi.org/10.1186/s10194-017-0793-3
work_keys_str_mv AT zhanghaifeng singledosebotulinumtoxintypeacomparedwithrepeateddosefortreatmentoftrigeminalneuralgiaapilotstudy
AT lianyajun singledosebotulinumtoxintypeacomparedwithrepeateddosefortreatmentoftrigeminalneuralgiaapilotstudy
AT xienanchang singledosebotulinumtoxintypeacomparedwithrepeateddosefortreatmentoftrigeminalneuralgiaapilotstudy
AT chenchen singledosebotulinumtoxintypeacomparedwithrepeateddosefortreatmentoftrigeminalneuralgiaapilotstudy
AT zhengyake singledosebotulinumtoxintypeacomparedwithrepeateddosefortreatmentoftrigeminalneuralgiaapilotstudy